Table 2. Ongoing trialsusing checkpoint inhibitors in endometrial cancer.
| Combination | Treatment setting | Line of therapy | Phase | Primaryendpoint | Status | Trial identifer |
|---|---|---|---|---|---|---|
| aPD-L1 | Avelumab in Patients With MSS, MSI-H and POLE-mutated | 2L+ | 2 | PFS6 | Recruiting | NCT02912572 |
| aPD-1 | Pembrolizumab in Ultramutated and Hypermutated EC | 2L+ | 2 | ORR, safety by CTCAE v4 | Recruiting | NCT02899793 |
| aPD-1 | Pembrolizumab on the TumoralImmunoprofile of Gynecologic Cancers | 1L | 1 | Tumor immune infiltrates | Recruiting | NCT02728830 |
| aPD-1 | MK-3475 Immunotherapy in Endometrial Carcinoma | 1L | 1 | Safety by CTCAE v4 | Recruiting | NCT02630823 |
| aPD-1 + Chemo | Pembro/Carbo/Taxol | 1L+ | 2 | ORR | Not yet recruiting | NCT02549209 |
| aPD-1 + Bev/C/PLD | IMGN853 + Bevacizumab, Carboplatin, PLD or Pembrolizumab | 2L+ | 1 | ORR, SAEs, TEAEs | Recruiting | NCT02606305 |
| aPD-1 + TKI | Pembrolizumab + Lenvatinib | 2L+ | 1b/2 | MTD, DLTs, ORR | Recruiting | NCT02501096 |
| aPD-1 + TIL | Pembrolizubab+ TIL PBL and aldesleukin | 2L+ | 2 | ORR | Recruiting | NCT01174121 |
| aPD-1 + TKI | Pembrolizumab +Itacitinib | 2L+ | 1 | Safety by CTCAE v4 | Recruiting | NCT02646748 |
| aPD-L1 + aCTLA-4 | Durvalumab +/− Tremelimumab | 2L+ | 2 | ORR | Recruiting | NCT03015129 |
| aPD-1 + Chemo | Nivolumab + Chemotherapy | 2L+ | 1b/2 | RP2D | Recruiting | NCT02423954 |
| aPD-1 + aCTLA-4 | Nivolumab + Ipilimumab | 2L+ | 2 | ORR | Not yet recruiting | NCT02982486 |
| aPD-1 + mTORi | Nivolumab + Temsirolimus/ Nivolumab + CT | 2L+ | 1b/2 | RP2D | Recruiting | NCT02423954 |
| aPD-1 + aCTLA-4 | Nivolumab + Ipilimumab in rare tumors | 1L+ | 2 | ORR | Recruiting | NCT02834013 |
| aPD-L1 + Chemo | Atezolizumab + Carboplatin-cyclophosphamide | 2L | 1 | Toxicity by CTCAE v4 | Recruiting | NCT02914470 |
| aPD-L1 + IDO Inhibithor | Atezolizumab + GDC-0919 | 2L+ | 1 | DLT, SAEs | Recruiting | NCT02471846 |
Chemo, chemotherapy; Bev, bevacizumab; C, Carboplatin; PLD, pegylatedliposomaldoxorubicin; TKI, tyrosine-kinaseinhibitor; TIL, tumorinfiltratinglymphocytes; mTORi, mTORinhibitor; IDO, indoleamine 2,3-dioxigenase; L, line (regime of chemotherapy); PFS6, progression free survivalat 6 months;ORR, overallresponse rate; CTCAE v4, Common TerminologyCriteria for AdverseEvents, version 4.03; SAEs, seriousadverseevents; TEAEs, treatment-emergentadverseevents; MTD,maximum tolerated dose; DLT, dose-limitingtoxicities; RP2D, recommendedphase 2 dose; NCT, National Clinical Trial.